McIntyre, Freedman & Flynn Investment Advisers’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $278K | Buy |
6,000
+1,000
| +20% | +$46.3K | 0.2% | 56 |
|
|
2025
Q1 | $305K | Sell |
5,000
-52
| -1% | -$3.17K | 0.22% | 54 |
|
|
2024
Q4 | $286K | Sell |
5,052
-1,000
| -17% | -$56.6K | 0.21% | 55 |
|
|
2024
Q3 | $313K | Sell |
6,052
-1,000
| -14% | -$51.7K | 0.22% | 53 |
|
|
2024
Q2 | $293K | Buy |
+7,052
| New | +$293K | 0.21% | 54 |
|
|
2023
Q4 | – | Sell |
-8,051
| Closed | -$467K | – | 67 |
|
|
2023
Q3 | $467K | Buy |
8,051
+1,000
| +14% | +$58K | 0.39% | 49 |
|
|
2023
Q2 | $451K | Buy |
7,051
+900
| +15% | +$57.6K | 0.39% | 46 |
|
|
2023
Q1 | $426K | Buy |
6,151
+1,100
| +22% | +$76.2K | 0.36% | 48 |
|
|
2022
Q4 | $363K | Buy |
+5,051
| New | +$363K | 0.3% | 50 |
|